Atul Bedi

Associate Professor

School of Medicine

If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

2 Similar Profiles

Apoptosis Medicine & Life Sciences

Neoplasms Medicine & Life Sciences

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences

Phosphotransferases Medicine & Life Sciences

Tumors Chemical Compounds

Cell Death Medicine & Life Sciences

DNA Damage Medicine & Life Sciences

Death Domain Receptors Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1993 2018

41 Article
1 Chapter

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

Ravi, R., Noonan, K., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., Artemov, A. V., Wysocki, P. T., Mehra, R., Nimmagadda, S., Marchionni, L., Sidransky, D., Borrello, I. M., Izumchenko, E. & Bedi, A., Dec 1 2018, In : Nature Communications. 9, 1, 741.

Research output: Contribution to journal › Article

beta factor

CTLA-4 Antigen

antibodies

Transforming Growth Factor beta

Immunotherapy

Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors

Izumchenko, E., Paz, K., Ciznadija, D., Sloma, I., Katz, A., Vasquez-Dunddel, D., Ben-Zvi, I., Stebbing, J., McGuire, W., Harris, W., Maki, R., Gaya, A., Bedi, A., Zacharoulis, S., Ravi, R., Wexler, L. H., Hoque, M., Rodriguez-Galindo, C., Pass, H., Peled, N. & 4 othersDavies, A., Morris, R., Hidalgo, M. & Sidransky, D., 2017, In : Annals of Oncology. 28, 10, p. 2595-2605 11 p.

Research output: Contribution to journal › Article

Heterografts

Neoplasms

Therapeutics

Exome

Translational Medical Research

SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in head and neck cancer cells

Ozawa, H., Ranaweera, R. S., Izumchenko, E., Makarev, E., Zhavoronkov, A., Fertig, E., Howard, J. D., Markovic, A., Bedi, A., Ravi, R., Perez, J., Le, Q. T., Kong, C. S., Jordan, R. C., Wang, H., Kang, H., Quon, H., Sidransky, D. & Chung, C. H., Sep 1 2017, In : Clinical Cancer Research. 23, 17, p. 5162-5175 14 p.

Research output: Contribution to journal › Article

Head and Neck Neoplasms

Gene Knockdown Techniques

Phenotype

Cell Line

Cetuximab

Patient-derived xenografts as tools in pharmaceutical development

Izumchenko, E., Meir, J., Bedi, A., Wysocki, P. T., Hoque, M. & Sidransky, D., 2016, (Accepted/In press) In : Clinical Pharmacology and Therapeutics.

Research output: Contribution to journal › Article

Heterografts

Pharmaceutical Preparations

Neoplasms

Decision Making

Therapeutics

A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma

Gilbert, J., Schell, M. J., Zhao, X., Murphy, B., Tanvetyanon, T., Leon, M. E., Hayes, D. N., Haigentz, M., Saba, N., Nieva, J., Bishop, J., Sidransky, D., Ravi, R., Bedi, A. & Chung, C. H., 2015, In : Oral Oncology. 51, 4, p. 376-382 7 p.

Research output: Contribution to journal › Article

Disease-Free Survival

Neoplasms

Cytokines

Human papillomavirus 6

Cetuximab